Usefulness of Ivermectin in COVID-19 Illness

12 Pages Posted:

See all articles by Amit Patel

Amit Patel

University of Utah - Department of Biomedical Engineering

Date Written: April 19, 2020


Importance: There is no established anti-viral therapy for treating COVID-19 illness.

Objective: To study the usefulness of Ivermectin, an antimicrobial therapy, in COVID-19 outcomes.

Design: An international, multicenter, observational propensity-score matched case-controlled study using prospectively collected data on patients diagnosed with COVID-19 between January 1, 2020 and March 31, 2020.

Setting: An international multi- institutional deidentified healthcare outcomes database.

Participants: Hospitalized patients diagnosed with COVID-19 determined by presence of a positive laboratory finding confirming SARS-CoV-2 infection.

Exposure: Ivermectin (150mcg/Kg) administered once compared with COVID-19 patients receiving medical therapy without ivermectin.

Main Outcome: The principal outcome was to assess the association of ivermectin administration with survival in COVID-19.

Results: The cohort (including 704 ivermectin treated and 704 controls) was derived from 169 hospitals across 3 continents with COVID-19 illness. The patients were matched for age, sex, race or ethnicity, comorbidities and a illness severity score (qSOFA). Of those requiring mechanical ventilation fewer patients died in the ivermectin group (7.3% versus 21.3%) and overall death rates were lower with ivermectin (1.4% versus 8.5%; HR 0.20 CI 95% 0.11-0.37, p<0.0001).

Conclusions and Relevance: The administration of ivermectin during COVID-19 illness in hospitalized patients is associated with a lower mortality and hospital length of stay. These findings require confirmation in randomized controlled trials.

Note: Conflict of Interest: Dr. Mehra reports no direct conflicts pertinent to the development of this paper. Other general conflicts include consulting relationships with Abbott, Medtronic, Janssen, Mesoblast, Portola, Bayer, NupulseCV, FineHeart, Leviticus and Triple Gene. Dr. Desai is the founder of Surgisphere Corporation, Chicago, IL. The other authors have no pertinent conflicts to report.

Ethical Approval: The data analyses are deemed exempt from ethics review.

Keywords: covid19, ivermectin, outcomes

Suggested Citation

Patel, Amit, Usefulness of Ivermectin in COVID-19 Illness (April 19, 2020). Available at SSRN:

Amit Patel (Contact Author)

University of Utah - Department of Biomedical Engineering ( email )

1645 E. Campus Center
Salt Lake City, UT 84112
United States

Here is the Coronavirus
related research on SSRN

Paper statistics

Abstract Views
PlumX Metrics